PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34569654-3	2021	Treatment with Roxadustat led to significantly accelerated compensatory lung growth (CLG) through downregulation of pigment epithelium-derived factor (PEDF), an anti-angiogenic factor, rather than upregulation of vascular endothelial growth factor (VEGF).	roxadustat	15-25	vascular endothelial growth factor A	Homo sapiens	213-247	
34569654-3	2021	Treatment with Roxadustat led to significantly accelerated compensatory lung growth (CLG) through downregulation of pigment epithelium-derived factor (PEDF), an anti-angiogenic factor, rather than upregulation of vascular endothelial growth factor (VEGF).	roxadustat	15-25	vascular endothelial growth factor A	Homo sapiens	249-253	
32666268-4	2020	In this study, we evaluated the potential for Roxadustat (FG-4592), a prolyl hydroxylase inhibitor known to increase endogenous VEGF, in accelerating compensatory lung growth.	roxadustat	46-56	vascular endothelial growth factor A	Homo sapiens	128-132	
32666268-4	2020	In this study, we evaluated the potential for Roxadustat (FG-4592), a prolyl hydroxylase inhibitor known to increase endogenous VEGF, in accelerating compensatory lung growth.	roxadustat	58-65	vascular endothelial growth factor A	Homo sapiens	128-132	
30817065-4	2019	In vitro, we found that roxadustat could promote the angiogenic activity of human umbilical vein endothelial cells, accompanied by up-regulation of HIF-1alpha/VEGF/VEGFR2 signaling.	roxadustat	24-34	vascular endothelial growth factor A	Homo sapiens	159-163